Coronavirus (COVID-19)
Learn more
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent.
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hospital of Central Connecticut
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209